Novartis (NVS +0.4%) exercises its option to in-license privately held Lubris BioPharma's ECF843, a recombinant human lubricin, for ophthalmic indications including dry eye. The license is effective worldwide except Europe. Lubris retains the rights for non-ophthalmology uses. Financial terms are not disclosed.
Lubricin is a naturally occurring human protein that functions as a biological lubricant. A deficiency in this protein is common in dry eye sufferers.